Project Description



There is currently no specific antiviral treatment for COVID-19. For this project, researchers suggest to rapidly identify and characterize antiviral molecules which had or have a marketing authorization (MA) for the treatment of pathologies other than respiratory viral infections.


To reposition drugs showing the best antiviral activity for the treatment of COVID-19. In order to succeed, researchers are screening chemical libraries (molecule database) composed of the active ingredients of drugs with marketing authorisations on respiratory cells taken from humans and then infected with SARS-CoV-2. Compounds with the best antiviral activity will soon be available as part of a COVID-19 clinical trial currently being put in place on the Lille site.

Project initiator:

Jean Dubuisson